Kailera Therapeutics’ equity made a strong showing in its first session on the Nasdaq on Friday, advancing 62.5% from its offering price after completing a U.S. initial public offering intended to raise $625.0 million in gross proceeds.
The company’s stock began trading at $26 per share, a substantial premium to the $16 per share that served as the IPO price. Kailera priced the offering on Thursday, selling 39,062,500 shares of common stock at $16 per share and indicating expected gross proceeds of $625.0 million before underwriting discounts and offering expenses.
Kailera is a biotechnology firm focused on developing treatments for obesity. The offering list of joint book-running managers includes J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI, with William Blair serving as lead manager for the transaction.
Transaction details
- IPO price: $16 per share.
- Shares sold in offering: 39,062,500 common shares.
- Expected gross proceeds: $625.0 million before underwriting discounts and offering expenses.
- Opening trade on Nasdaq: $26 per share.
Market context and immediate outcome
The debut trading price represented a 62.5% increase over the IPO price, reflecting strong initial demand at the open. Kailera’s business focus on obesity treatments and the size of the offering are central to the financing, which was executed with a syndicate of prominent investment banks as joint book-runners and a named lead manager.
Summary of key facts
- The offering was priced on Thursday and began trading on Nasdaq on Friday.
- The company expects $625.0 million in gross proceeds from the sale of 39,062,500 shares at $16 per share.
- Book-running managers: J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI; lead manager: William Blair.
This report presents the factual details of Kailera Therapeutics’ IPO and its opening trading performance without commentary beyond the transaction and market response as reported.